Elevance Health price target lowered to $350 from $413 at Mizuho

Mizuho analyst Ann Hynes lowered the firm’s price target on Elevance Health (ELV) to $350 from $413 and keeps an Outperform rating on the shares. Elevance reiterated its 2026 guidance at a competitor conference and noted the Centers for Medicare and Medicaid Services sanctions are related to historical data submission processes and does not impact the company’s current risk-adjustment processes, the analyst tells investors in a research note. The firm notes Elevance expects that any impact is currently embedded within 2026E guidance.